{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:38:15Z","timestamp":1789432695191,"version":"build-2803163510"},"reference-count":288,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00888","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T06:45:10Z","timestamp":1589265910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice"],"prefix":"10.3389","volume":"11","author":[{"given":"Marco","family":"Cerrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo Giuseppe","family":"Faraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Maloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Sanchez-Escamilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Elsabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afraa","family":"Fadul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Maffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Pittari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1126\/science.3140379","article-title":"Single-chain antigen-binding proteins","volume":"242","author":"Bird","year":"1988","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"8905","DOI":"10.1073\/pnas.88.20.8905","article-title":"T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins","volume":"88","author":"Letourneur","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"aat6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"B9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/0092-8674(90)90341-B","article-title":"Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation","volume":"60","author":"Goverman","year":"1990","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2002-07-1989","article-title":"T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect","volume":"101","author":"Cooper","year":"2003","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Can. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1158\/2159-8290.CD-NB2017-169","article-title":"JCAR015 in ALL: a root-cause investigation","volume":"8","author":"Poh","year":"2018","journal-title":"Cancer Discov"},{"key":"B28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in Relapsed\/Refractory (R\/R) large B cell Lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1200\/JCO.2019.37.15_suppl.7006","article-title":"End of phase I results of ZUMA-3, a phase 1\/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL)","volume":"37","author":"Shah","year":"2019","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1200\/JCO.2018.36.15_suppl.7006","article-title":"Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL)","volume":"36","author":"Shah","year":"2018","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/01.HS9.0000562152.07779.48","article-title":"Phase 1 results of zuma-4: kte-x19, an anti-cd19 chimeric antigen receptor t cell therapy, in pediatric and adolescent patients with relapsed\/refractory b cell acute lymphoblastic leukemia: ps962","volume":"3","author":"Wayne","year":"2019","journal-title":"HemaSphere"},{"key":"B33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/ refractory B cell non-Hodgkin lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.1200\/JCO.2017.35.15_suppl.7028","article-title":"Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed\/refractory acute lymphocytic leukemia in a multicenter trial","volume":"35","author":"Xiao","year":"2017","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell all patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-Cell acute lymphoblastic leukemia","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/hon.128_2629","article-title":"Safety of lisocabtagene maraleucel given with durvalumab in patients with relapsed\/refractory aggressive B-cell non hodgkin lymphoma: first results from the platform study","volume":"37","author":"Siddiqi","year":"2019","journal-title":"Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1182\/blood-2018-99-116745","article-title":"Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed\/refractory aggressive B-cell non-hodgkin lymphoma","volume":"132","author":"Hirayama","year":"2018","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/JCO.2019.37.15_suppl.7501","article-title":"TRANSCEND CLL 004: Minimal Residual Disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL)","volume":"37","author":"Siddiqi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1182\/blood-2018-99-115418","article-title":"Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate","volume":"132","author":"Gill","year":"2018","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified t cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hon.2437_7","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory,aggressive Non-Hodgkin Lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"24","author":"Chou","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"HemaSphere"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood.V128.22.2159.2159","article-title":"Kinase inhibitor ibrutinib prevents cytokine-release syndrome after Anti-CD19 chimeric antigen receptor T cells (CART) for B cell neoplasms","volume":"128","author":"Ruella","year":"2016","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"aau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"key":"B66","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1200\/JCO.2016.34.15_suppl.7002","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"34","author":"Frey","year":"2019","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B72","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","article-title":"Potent anti-leukemia activities of chimeric antigen receptor-modified t cells against CD19 in chinese patients with relapsed\/refractory acute lymphocytic leukemia","volume":"23","author":"Hu","year":"2017","journal-title":"Clin Can Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell Therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor t-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1182\/blood-2018-99-116539","article-title":"Prediction of CAR T-related toxicities in R\/R DLBCL patients treated with axicabtagene ciloleucel using point of care cytokine measurements","volume":"132","author":"Faramand","year":"2018","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor-modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"B85","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood-2019-126218","article-title":"CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1056\/NEJMoa051568","article-title":"An antibody-deficiency syndrome due to mutations in the CD19 gene","volume":"354","author":"van Zelm","year":"2006","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood.2019001859","article-title":"A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells","volume":"135","author":"Ruella","year":"2019","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1182\/blood.V128.22.999.999","article-title":"T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial","volume":"128","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2741\/4780","article-title":"Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives","volume":"24","author":"Coscia","year":"2019","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR Is modulated by target epitope distance from the cell membrane","volume":"180","author":"James","year":"2008","journal-title":"J Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","article-title":"Modulation of target antigen density improves CAR T-cell functionality and persistence","volume":"25","author":"Ramakrishna","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"B103","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","article-title":"Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia","volume":"14","author":"Baskar","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/ijc.23587","article-title":"Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy","volume":"123","author":"Daneshmanesh","year":"2008","journal-title":"Int J Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1158\/0008-5472.CAN-10-2662","article-title":"Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis","volume":"71","author":"Gentile","year":"2011","journal-title":"Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer immunology research"},{"key":"B108","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B109","doi-asserted-by":"publisher","first-page":"e1326437","DOI":"10.1080\/2162402X.2017.1326437","article-title":"An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors","volume":"6","author":"Gohil","year":"2017","journal-title":"Oncoimmunology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1038\/s41375-018-0113-1","article-title":"First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells","volume":"32","author":"Hojjat-Farsangi","year":"2018","journal-title":"Leukemia"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1182\/bloodadvances.2018029678","article-title":"Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma","volume":"3","author":"Koksal","year":"2019","journal-title":"Blood Adv"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarfo","year":"2018","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of tumor destruction by chimeric antigen receptor-modified T cells","volume":"22","author":"Anurathapan","year":"2014","journal-title":"Mol Ther"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B116","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"B117","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Can Immunol Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/JCO.2019.37.15_suppl.2510","article-title":"Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma","volume":"37","author":"Shah","year":"2019","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1182\/blood.V126.23.4427.4427","article-title":"Preclinical development of bispecific chimeric antigen receptor targeting both CD19 and CD22","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e26286","DOI":"10.4161\/onci.26286","article-title":"Blockade of PD-1 immunosuppression boosts CAR T-cell therapy","volume":"2","author":"John","year":"2013","journal-title":"Oncoimmunology"},{"key":"B123","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/1078-0432.CCR-15-1070","article-title":"Blockade of programmed death 1 augments the ability of human t cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer","volume":"22","author":"Moon","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of phase 1 results from zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell Lymphoma","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2014-07-589069","article-title":"Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia","volume":"125","author":"Audrito","year":"2015","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1182\/blood-2012-03-417519","article-title":"Dysfunctional Vgamma9Vdelta2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells","volume":"120","author":"Coscia","year":"2012","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1832968","DOI":"10.1155\/2017\/1832968","article-title":"Regulatory T cells and their prognostic relevance in hematologic malignancies","volume":"2017","author":"D'Arena","year":"2017","journal-title":"J Immunol Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3324\/haematol.2013.095281","article-title":"HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism","volume":"99","author":"Rizzo","year":"2014","journal-title":"Haematologica"},{"key":"B131","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"key":"B132","doi-asserted-by":"publisher","first-page":"e1057385","DOI":"10.1080\/2162402X.2015.1057385","article-title":"Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"Oncoimmunology"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib\u2013findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1182\/blood-2018-99-116068","article-title":"Ibrutinib treatment mitigates phenotypic alterations of non-neoplastic immune cell compartments in chronic lymphocytic leukemia","volume":"132","author":"Griggio","year":"2018","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the BTK inhibitor ibrutinib to anti-CD19 Chimeric Antigen Receptor T Cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother CII"},{"key":"B138","doi-asserted-by":"publisher","first-page":"98200","DOI":"10.18632\/oncotarget.21516","article-title":"Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(-) T-cells","volume":"8","author":"Neuber","year":"2017","journal-title":"Oncotarget"},{"key":"B139","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov"},{"key":"B141","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","first-page":"99753","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1158\/0008-5472.CAN-16-1577","article-title":"Armed oncolytic adenovirus-expressing pd-l1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors","volume":"77","author":"Tanoue","year":"2017","journal-title":"Cancer Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","article-title":"Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B146","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1126\/science.270.5238.908a","article-title":"IL-12 deaths: explanation and a puzzle","volume":"270","author":"Cohen","year":"1995","journal-title":"Science"},{"key":"B147","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"B148","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med"},{"key":"B149","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"B151","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B152","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B153","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"key":"B154","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e1378842","DOI":"10.1080\/2162402X.2017.1378842","article-title":"Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors","volume":"7","author":"Kunert","year":"2017","journal-title":"Oncoimmunology"},{"key":"B156","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","article-title":"Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor","volume":"31","author":"Foster","year":"2008","journal-title":"J Immunother"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","article-title":"Reversal of tumor immune inhibition using a chimeric cytokine receptor","volume":"22","author":"Leen","year":"2014","journal-title":"Mol Ther"},{"key":"B160","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol Ther"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"B162","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"B163","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B164","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood-2018-99-117737","article-title":"A phase I first-in-human clinical trial of CD19-targeted 19-28z\/4-1BBL \u201cArmored\u201d CAR T cells in patients with relapsed or refractory NHL and CLL including richtes transformation","volume":"132","author":"Park","year":"2018","journal-title":"Blood"},{"key":"B165","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nature Biotechnol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"di Stasi","year":"2009","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"B168","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nature Biotechnol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/mt.2014.156","article-title":"Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells","volume":"23","author":"Iwahori","year":"2015","journal-title":"Mol Ther"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol Ther"},{"key":"B171","doi-asserted-by":"publisher","first-page":"27130","DOI":"10.1038\/srep27130","article-title":"T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive malignancies","volume":"6","author":"Velasquez","year":"2016","journal-title":"Sci Rep"},{"key":"B172","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bbmt.2017.10.017","article-title":"Building a safer and faster CAR: seatbelts, airbags, and CRISPR","volume":"24","author":"Perales","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B176","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B177","doi-asserted-by":"publisher","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B178","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14656566.2017.1293655","article-title":"Magic pills: new oral drugs to treat chronic lymphocytic leukemia","volume":"18","author":"Vitale","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"B179","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood-2017-03-772285","article-title":"In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI","volume":"129","author":"Rigolin","year":"2017","journal-title":"Blood"},{"key":"B180","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s40425-019-0686-x","article-title":"State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in (2019)","volume":"7","author":"Lemal","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B181","doi-asserted-by":"publisher","first-page":"TPS7566","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7566","article-title":"ZUMA-8: a phase 1\/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Front Immunol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent Ibrutinib for CLL after ibrutinib failure","author":"Gauthier","year":"2020","journal-title":"Blood."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1182\/blood-2016-01-692046","article-title":"Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells","volume":"128","author":"Faitschuk","year":"2016","journal-title":"Blood"},{"key":"B186","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1182\/blood-2010-10-311845","article-title":"In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor","volume":"117","author":"Giordano Attianese","year":"2011","journal-title":"Blood"},{"key":"B187","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1182\/blood.V130.Suppl__1.740.740","article-title":"Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-bcma CAR T cell therapy","volume":"130","author":"Berdeja","year":"2017","journal-title":"Blood"},{"key":"B188","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B189","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B193","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B195","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric antigen receptor-modified t cell therapy in multiple myeloma: beyond b cell maturation antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front Immunol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"B198","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/gt.2010.21","article-title":"Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen","volume":"17","author":"Peinert","year":"2010","journal-title":"Gene Ther"},{"key":"B199","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1182\/blood.V128.22.4052.4052","article-title":"Safety data from a first-in-human phase 1 trial of NKG2D chimeric antigen receptor-T cells in AML\/MDS and multiple myeloma","volume":"128","author":"Nikiforow","year":"2016","journal-title":"Blood"},{"key":"B200","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1182\/blood.V130.Suppl__1.3142.3142","article-title":"Chimeric antigen receptor (CAR) T cells specific for CD229: a potentially curative approach for multiple myeloma","volume":"130","author":"Venniyil Radhakrishnan","year":"2017","journal-title":"Blood"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat Med"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase i trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B203","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"key":"B204","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.bbmt.2018.12.145","article-title":"CD30-Chimeric Antigen Receptor (CAR) T cells for therapy of Hodgkin Lymphoma (HL)","volume":"25","author":"Ramos","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"B205","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric antigen receptors for T-cell malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Front Oncol"},{"key":"B206","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"B207","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"Sanchez-Martinez","year":"2019","journal-title":"Blood"},{"key":"B208","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1038\/s41375-019-0484-y","article-title":"Correction: unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies","volume":"33","author":"Huang","year":"2019","journal-title":"Leukemia."},{"key":"B209","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"B210","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11912-019-0764-8","article-title":"New Treatment Options for Acute Myeloid Leukemia in (2019)","volume":"21","author":"Cerrano","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B211","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B212","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/jcm8020200","article-title":"Chimeric Antigen Receptor (CAR) T cell therapy in Acute Myeloid Leukemia (AML)","volume":"8","author":"Hofmann","year":"2019","journal-title":"J Clin Med"},{"key":"B213","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","article-title":"Will CAR T cell therapy have a role in AML? promises and pitfalls","volume":"56","author":"Cummins","year":"2019","journal-title":"Semin Hematol"},{"key":"B214","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"B216","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol Immunother CII"},{"key":"B218","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"B219","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","article-title":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination","volume":"132","author":"Akahori","year":"2018","journal-title":"Blood"},{"key":"B220","doi-asserted-by":"publisher","first-page":"e458","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J"},{"key":"B221","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1182\/blood.V130.Suppl_1.1359.1359","article-title":"Treating Relapsed \/ Refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"B223","doi-asserted-by":"publisher","first-page":"e0166891","DOI":"10.1371\/journal.pone.0166891","article-title":"In Vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor t-cells for acute myeloid leukemia","volume":"11","author":"Minagawa","year":"2016","journal-title":"PLoS One"},{"key":"B224","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1080\/10428194.2017.1375107","article-title":"Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse","volume":"59","author":"Cummins","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B226","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B227","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1158\/2326-6066.CIR-18-0748","article-title":"T-cell activity against AML improved by dual-targeted T cells stimulated through T-cell and IL7 receptors","volume":"7","author":"Krawczyk","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J Clin Immunol"},{"key":"B229","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-018-0646-9","article-title":"Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy","volume":"11","author":"Zhang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"B232","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","article-title":"Targeting alpha-Fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B233","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"B234","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1042\/BST20150249","article-title":"The integrin alphavbeta6: a novel target for CAR T-cell immunotherapy?","volume":"44","author":"Whilding","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"B235","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol Ther"},{"key":"B236","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/ijms19020340","article-title":"Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-In CAR-T","volume":"19","author":"Yoon","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B237","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B238","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s13238-017-0410-x","article-title":"Advancing chimeric antigen receptor T cell therapy with CRISPR\/Cas9","volume":"8","author":"Ren","year":"2017","journal-title":"Protein Cell"},{"key":"B239","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11899-017-0417-7","article-title":"Genome-editing technologies in adoptive T cell immunotherapy for cancer","volume":"12","author":"Singh","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"B240","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"B241","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nbt1410","article-title":"Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases","volume":"26","author":"Perez","year":"2008","journal-title":"Nat Biotechnol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt.1755","article-title":"A TALE nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2011","journal-title":"Nat Biotechnol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/mt.2015.197","article-title":"Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas9, and megaTAL nucleases","volume":"24","author":"Osborn","year":"2016","journal-title":"Mol Ther"},{"key":"B244","doi-asserted-by":"publisher","first-page":"307ra156","DOI":"10.1126\/scitranslmed.aac5530","article-title":"Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template","volume":"7","author":"Sather","year":"2015","journal-title":"Sci Transl Med"},{"key":"B245","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"B246","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol Ther"},{"key":"B247","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"B248","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B249","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1172\/JCI65899","article-title":"Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance","volume":"124","author":"Jandus","year":"2014","journal-title":"J Clin Invest"},{"key":"B250","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"B251","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B252","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1182\/blood-2018-99-116843","article-title":"Pluripotent cell-derived off-the-shelf TCR-less CAR-targeted cytotoxic T cell therapeutic for the allogeneic treatment of B cell malignancies","volume":"132","author":"Clarke","year":"2018","journal-title":"Blood"},{"key":"B253","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.molmed.2009.04.005","article-title":"Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors","volume":"15","author":"Rey","year":"2009","journal-title":"Trends Mol Med"},{"key":"B254","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41375-019-0613-7","article-title":"Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia","volume":"34","author":"Quintarelli","year":"2019","journal-title":"Leukemia."},{"key":"B255","doi-asserted-by":"publisher","first-page":"e76781","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PloS One"},{"key":"B256","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"B257","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B258","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"B259","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.1365-2249.2002.01919.x","article-title":"Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line","volume":"129","author":"Reid","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B260","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","article-title":"Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells","volume":"33","author":"Boissel","year":"2009","journal-title":"Leukemia Res"},{"key":"B261","doi-asserted-by":"publisher","first-page":"e26527","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Boissel","year":"2013","journal-title":"Oncoimmunology"},{"key":"B262","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jcmm.12810","article-title":"CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies","volume":"20","author":"Romanski","year":"2016","journal-title":"J Cell Mol Med"},{"key":"B263","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B264","unstructured":"WEBF\n          IEC, 2018: FACT WEB 2018"},{"key":"B265","unstructured":"WEBF\n          HCT, 2018: FACT WEB 2018"},{"key":"B266","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B267","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","article-title":"Building blocks for institutional preparation of CTL019 delivery","volume":"19","author":"McGuirk","year":"2017","journal-title":"Cytotherapy"},{"key":"B268","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","article-title":"Building a CAR garage: preparing for the delivery of commercial CAR T cell products at memorial sloan kettering cancer center","volume":"24","author":"Perica","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B269","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B270","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1188\/19.CJON.S1.13-19","article-title":"Associated toxicities: assessment and management related to CAR T-cell therapy","volume":"23","author":"Anderson","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"B271","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1634\/theoncologist.2019-0395","article-title":"Axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist","volume":"25","author":"Jacobson","year":"2020","journal-title":"Oncologist"},{"key":"B272","unstructured":"WEBE\n          EMA, 2018: EMA WEB 2018"},{"key":"B273","unstructured":"WEBE\n          APPENDIX, 2018: EMA WEB 2018"},{"key":"B274","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/01.HS9.0000562044.39405.b4","article-title":"Safety and efficacy of tisagenlecleucel (CTL019) in b acute lymphoblastic leukemia in children and young adults: robert debr\u00e9 and saint louis hospitals experience: PS943","volume":"3","author":"Dourthe","year":"2019","journal-title":"HemaSphere"},{"key":"B275","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/blood-2018-99-117199","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"B276","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-cell therapy for Relapsed\/Refractory large B-cell lymphoma: real world experience","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"key":"B277","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR-T cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood."},{"key":"B278","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","article-title":"Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)\u2013an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone Marrow Transplantation."},{"key":"B279","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"key":"B280","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/hon.2437_127","article-title":"High durable CR rates in Relapsed\/Refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort","volume":"130","author":"Abramson","year":"2017","journal-title":"Blood"},{"key":"B281","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.hoc.2019.03.005","article-title":"Allogeneic stem cell transplantation and Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of non-hodgkin lymphoma","volume":"33","author":"Hunter","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"B282","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood.2018883421","article-title":"CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"134","author":"Sauter","year":"2019","journal-title":"Blood"},{"key":"B283","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2018","journal-title":"J Natl Cancer Inst."},{"key":"B284","doi-asserted-by":"publisher","first-page":"e190035","DOI":"10.1001\/jamanetworkopen.2019.0035","article-title":"Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma","volume":"2","author":"Whittington","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B285","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","journal-title":"J Med Econ"},{"key":"B286","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large b-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"B287","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"B288","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1182\/blood-2018-99-116566","article-title":"Point-of-care manufacturing of CD20.19 bi-specific Chimeric Antigen Receptor T (CAR-T) cells in a standard academic cell processing facility for a phase i clinical trial in relapsed, refractory NHL","volume":"132","author":"Zhu","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00888\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T06:45:21Z","timestamp":1589265921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00888\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":288,"alternative-id":["10.3389\/fimmu.2020.00888"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00888","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"article-number":"888"}}